KTRA Kintara Therapeutics Inc: רווח למניה ב-12 החודשים האחרונים

High demand for brain tumor medications creates excellent sales prospects for Kintara Therapeutics (KTRA). The YoY ttm change in net income per share allows for a real-time assessment of capital freeze risks, and 24.50 shows the level of this metric. Business resilience is limited by a lack of recurring revenue and a dependence on grants, while global conflicts complicate patent protection and component logistics.
KTRA (Kintara Therapeutics Inc): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator reflects the rolling annual trend of net earnings per share, measuring the efficiency of business capitalization amid interest rate volatility. For Kintara Therapeutics (KTRA), this metric is critical due to costly oncology research and liquidity shortage risks. By analyzing the EPS growth rate over the last 12 months YoY, an investor can discern the company's actual resilience to operating losses. A negative trend here signals a threat to the issuer's survival.